Table 1 Baseline demographics and phenotypes in the investigated TAM-treated breast cancer patients (n = 40). Data are reported as the mean and 95% CI or percent

Age at diagnosis (years)

45.3 (44.70–45.90)

66.8 (66.13–67.46)

BMI (kg/m²)

29.58 (28.90–30.25)

28.07 (27.58–28.56)

Color (%)

white (85), non-white (15)

white (75), non-white (25)

Cancer type (%)

ductal in situ (5), invasive ductal (90) and invasive lobular (5)

ductal in situ (0), invasive ductal (90) and invasive lobular (10)

HER2 status (%)

positive (20), negative (75) and unknown (5)

positive (10), negative (80) and unknown (10)

Chemotherapy (%)

Yes (20) and No (80)

Yes (5) and No (95)

CYP2D6 phenotype (MR)

0.25 (0.21–0.30)

0.24 (0.19–0.29)

Midazolam oral clearance (mL/min/kg)

30.09 (21.55–42.02)

24.10 (19.41–29.92)